{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:54:04Z","timestamp":1768438444857,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA, Darmstadt, Germany","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40120-025-00849-0","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:15:44Z","timestamp":1762323344000},"page":"61-77","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Guiding Multiple Sclerosis Care: An Update to the 2013 Consensus Statement from the MS in the 21st Century Steering Group"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5436-5804","authenticated-orcid":false,"given":"Raed","family":"Alroughani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9127-6488","authenticated-orcid":false,"given":"Elisabeth G.","family":"Celius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4030-9291","authenticated-orcid":false,"given":"Elisabeth","family":"Kasilingam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6225-2161","authenticated-orcid":false,"given":"Paola","family":"Kruger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Montague","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9221-5716","authenticated-orcid":false,"given":"Celia","family":"Oreja-Guevara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7250-2576","authenticated-orcid":false,"given":"Amber","family":"Plant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maija","family":"Pontaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6921-0135","authenticated-orcid":false,"given":"Peter","family":"Rieckmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6581-0483","authenticated-orcid":false,"given":"Marja-Liisa","family":"Sumelahti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"issue":"10422","key":"849_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","volume":"403","author":"D Jakimovski","year":"2024","unstructured":"Jakimovski D, Bittner S, Zivadinov R, et al. Multiple sclerosis. Lancet. 2024;403(10422):183\u2013202.","journal-title":"Lancet"},{"key":"849_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101453","volume":"36","author":"J Lechner-Scott","year":"2019","unstructured":"Lechner-Scott J, Waubant E, Levy M, Hawkes C. Silent symptoms of multiple sclerosis. Mult Scler Relat Disord. 2019;36:101453.","journal-title":"Mult Scler Relat Disord"},{"key":"849_CR3","doi-asserted-by":"publisher","first-page":"1376095","DOI":"10.3389\/fnhum.2024.1376095","volume":"18","author":"SS Ayache","year":"2024","unstructured":"Ayache SS, Chalah MA. Neuroimaging and neuromodulation of invisible symptoms in multiple sclerosis. Front Hum Neurosci. 2024;18:1376095.","journal-title":"Front Hum Neurosci"},{"issue":"14","key":"849_CR4","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition. Mult Scler. 2020;26(14):1816\u201321.","journal-title":"Mult Scler"},{"key":"849_CR5","unstructured":"Number of people with MS | Atlas of MS. MS International Federation. https:\/\/www.atlasofms.org\/map\/global\/epidemiology\/number-of-people-with-ms. Accessed 27 Aug 2025."},{"issue":"4","key":"849_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11940-021-00666-4","volume":"23","author":"KM Krysko","year":"2021","unstructured":"Krysko KM, Bove R, Dobson R, Jokubaitis V, Hellwig K. Treatment of women with multiple sclerosis planning pregnancy. Curr Treat Options Neurol. 2021;23(4):11.","journal-title":"Curr Treat Options Neurol"},{"issue":"1","key":"849_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12883-023-03148-z","volume":"23","author":"F Pourhaji","year":"2023","unstructured":"Pourhaji F, Peyman N, Taraghdar MM, Jamali J, Tehrani H. Explaining the burden of psychosocial factors on the worsening symptoms of MS: a qualitative study of patients\u2019 experiences. BMC Neurol. 2023;23(1):98.","journal-title":"BMC Neurol"},{"issue":"7","key":"849_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60071033","volume":"60","author":"A Kantanis","year":"2024","unstructured":"Kantanis A, Pelantaki M, Fountaki ML, et al. Stress and quality of life in caregivers of patients with multiple sclerosis. Medicina (Kaunas). 2024;60(7):1033.","journal-title":"Medicina (Kaunas)"},{"key":"849_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103864","volume":"63","author":"AA Sarhan","year":"2022","unstructured":"Sarhan AA, El-Sharkawy KA, Mahmoudy AM, Hashim NA. Burden of multiple sclerosis: impact on the patient, family and society. Mult Scler Relat Disord. 2022;63:103864.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"849_CR10","volume":"1","author":"M Gonzalez-Lorenzo","year":"2024","unstructured":"Gonzalez-Lorenzo M, Ridley B, Minozzi S, et al. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2024;1(1):Cd011381.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"849_CR11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13643-022-01997-2","volume":"11","author":"T Lehnert","year":"2022","unstructured":"Lehnert T, R\u00f6ver C, K\u00f6pke S, et al. Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)-a systematic review protocol. Syst Rev. 2022;11(1):134.","journal-title":"Syst Rev"},{"issue":"4","key":"849_CR12","volume":"10","author":"C Heesen","year":"2024","unstructured":"Heesen C, R\u00f6ver C, Salem S, et al. Treatment effect modifiers of immunotherapies for relapsing-remitting multiple sclerosis-a systematic review and meta-analysis. Mult Scler J Exp Transl Clin. 2024;10(4):20552173241274618.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"2","key":"849_CR13","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s00415-012-6656-6","volume":"260","author":"P Rieckmann","year":"2013","unstructured":"Rieckmann P, Boyko A, Centonze D, et al. Future MS care: a consensus statement of the MS in the 21st Century Steering Group. J Neurol. 2013;260(2):462\u20139.","journal-title":"J Neurol"},{"issue":"5","key":"849_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/hex.70009","volume":"27","author":"OC Damman","year":"2024","unstructured":"Damman OC, Murugesu L, de Groot V, de Jong BA. \u2019So let\u2019s go on like this?\u2019-shared decision-making and the use of outcome information in routine care management for people with multiple sclerosis. Health Expect. 2024;27(5):e70009.","journal-title":"Health Expect"},{"key":"849_CR15","unstructured":"Web Annex A. World Health Organization model list of essential medicines \u2013 23rd list. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/289a875c-cc89-4914-90ad-eb3c578ebaf6\/content. Accessed 2 Oct 2025."},{"key":"849_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577627","volume":"357","author":"S Reyes","year":"2021","unstructured":"Reyes S, Cunningham AL, Kalincik T, et al. Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: an international consensus statement. J Neuroimmunol. 2021;357:577627.","journal-title":"J Neuroimmunol"},{"key":"849_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100979","volume":"44","author":"L Prosperini","year":"2024","unstructured":"Prosperini L, Arrambide G, Celius EG, et al. COVID-19 and multiple sclerosis: challenges and lessons for patient care. Lancet Reg Health Eur. 2024;44:100979.","journal-title":"Lancet Reg Health Eur"},{"issue":"6","key":"849_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41582-019-0183-3","volume":"15","author":"CB Vaughn","year":"2019","unstructured":"Vaughn CB, Jakimovski D, Kavak KS, et al. Epidemiology and treatment of multiple sclerosis in elderly populations. Nat Rev Neurol. 2019;15(6):329\u201342.","journal-title":"Nat Rev Neurol"},{"key":"849_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.106157","volume":"92","author":"N Al Worikat","year":"2024","unstructured":"Al Worikat N, Molaei F, Zanotto A, et al. Frailty in multiple sclerosis: a scoping review. Mult Scler Relat Disord. 2024;92:106157.","journal-title":"Mult Scler Relat Disord"},{"key":"849_CR20","unstructured":"European Medicines Agency. Clinical Trials Information System. 2025. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/clinical-trials-human-medicines\/clinical-trials-information-system."},{"key":"849_CR21","unstructured":"European Medicines Agency. Revised CTIS transparency rules 2023. https:\/\/www.ema.europa.eu\/en\/documents\/other\/revised-ctis-transparency-rules_en.pdf. Accessed 2 Oct 2025."},{"issue":"9","key":"849_CR22","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/brain\/awac016","volume":"145","author":"FD Lublin","year":"2022","unstructured":"Lublin FD, H\u00e4ring DA, Ganjgahi H, et al. How patients with multiple sclerosis acquire disability. Brain. 2022;145(9):3147\u201361.","journal-title":"Brain"},{"issue":"10","key":"849_CR23","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1177\/13524585241266180","volume":"30","author":"L Prosperini","year":"2024","unstructured":"Prosperini L, Ruggieri S, Haggiag S, Tortorella C, Gasperini C. Disability patterns in multiple sclerosis: a meta-analysis on RAW and PIRA in the real-world context. Mult Scler. 2024;30(10):1309\u201321.","journal-title":"Mult Scler"},{"key":"849_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100977","volume":"44","author":"E Portaccio","year":"2024","unstructured":"Portaccio E, Magyari M, Havrdova EK, et al. Multiple sclerosis: emerging epidemiological trends and redefining the clinical course. Lancet Reg Health Eur. 2024;44:100977.","journal-title":"Lancet Reg Health Eur"},{"key":"849_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1466339","volume":"15","author":"A van de Waterweg Berends","year":"2024","unstructured":"van de Waterweg Berends A, Broux B, Machiels B, Gillet L, Hellings N. The EBV-MS connection: the enigma remains. Front Immunol. 2024;15:1466339.","journal-title":"Front Immunol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00849-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00849-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00849-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:51:42Z","timestamp":1768398702000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00849-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["849"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00849-0","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Raed Alroughani received consulting fees for scientific advisory boards from Roche, Novartis, Sanofi, Biogen, AstraZeneca, and the healthcare business of Merck KGaA, Darmstadt, Germany; speaker honoraria from Roche, Novartis, Sanofi, AstraZeneca, the healthcare business of Merck KGaA, Darmstadt, Germany, and Lilly; and support for attending scientific meetings from Roche, the healthcare business of Merck KGaA, Darmstadt, Germany, Biogen, and AstraZeneca (no payment). Elisabeth G. Celius received lectures fees from the healthcare business of Merck KGaA, Darmstadt, Germany, Biogen, Sanofi, Novartis, Teva, Janssen-Cilag; and received consulting fees for advisory boards from the healthcare business of Merck KGaA, Darmstadt, Germany and Sanofi. Helen Gray is an employee of Merck Serono (Ireland) Ltd., Dublin, Ireland, an affiliate of Merck KGaA, Darmstadt, Germany. Elisabeth Kasilingam\u2019s institution (European Multiple Sclerosis Platform) received consulting fees from Roche, the healthcare business of Merck KGaA, Darmstadt, Germany, and Sanofi; she is Vice President of the European Patients\u2019 Forum (\n                      \n                      ). Paola Kruger received fees for participation as a patient advisor from the healthcare business of Merck KGaA, Darmstadt, Germany; and received fees for attending MS21 steering committee meetings from the healthcare business of Merck KGaA, Darmstadt, Germany. Amanda Montague\u2019s institution (Multiple Sclerosis Association of America) received grants and honorarium from Biogen, EMD Serono, Boston, MA, Sanofi, Genentech, TG Therapeutics, Bristol Myers Squibb, Mallinckrodt, and Novartis. Celia Oreja-Guevara received fees for speaking, consulting, and serving on advisory boards from Alexion, Amgen, Biogen IDEC, Bristol Myers Squibb, Horizon, Janssen, the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, Roche, Sanofi Genzyme, Sandoz,\u00a0Viatris, Neuraxpharm, and Teva. Amber Plant is an employee of Shift.ms. Maija Pontaga holds a role in the Latvian Multiple Sclerosis Association. Peter Rieckmann received fees for lectures from the healthcare business of Merck KGaA, Darmstadt, Germany and Sanofi. Leslie Ritter is a member of the American Brain Coalition Board and is the Vice President of the National MS Society, Healthcare Access. Marja-Liisa Sumelahti received consulting fees and honoraria from the healthcare business of Merck KGaA, Darmstadt, Germany, Organon, Teva, AbbVie, Gedeon Richter, Lundbeck, and Pfizer; support for meetings from the healthcare business of Merck KGaA, Darmstadt, Germany, Organon, Teva, AbbVie, Lundbeck, and Pfizer; and has participated in advisory boards for Teva, AbbVie, Lundbeck, and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was reviewed by an independent institutional review board, WCG, and determined to be exempt from full review. All voting was conducted anonymously. The manuscript does not contain clinical studies or patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}